Current Opinion in Investigational Drugs

Log on / register
Feedback | Support | My details

home journals A-Z subject areas advanced search authors reviewers libraries about my BioMed Central home journals A-Z subject areas advanced search authors reviewers libraries about my BioMed Central

Quick Search

	Current Opinion in Investigational Drugs
	BioMed Central
	PubMed Central
	PubMed

Jump to article


vol.	page no.

Current Opinion in Investigational Drugs

Home

Current Opinion in Investigational Drugs, Volume 10, Issue 6 (June 2009)

[more info]

Current Opinion in Investigational Drugs is published monthly and delivers systematic and comprehensive coverage of the following therapeutic areas: Anti-infectives; Anti-inflammatory, immune-meditated and gastrointestinal; Cardiovascular, renal and metabolic; Central and peripheral nervous system; Oncological

Access to the full text or PDF of articles from Current Opinion in Investigational Drugs requires a subscription to the journal.

previous issue

Paper alert
SA Antoniu, M Daneshtalab, S Doggrell, MJ Elices, RE Hurst, N Levens, M Williams
Current Opinion in Investigational Drugs 2009, 10:507-514 (5

June

2009)
[PDF]

Patent alert
HAM Mucke, P Norman, C Whelan, C Yeates
Current Opinion in Investigational Drugs 2009, 10:515-522 (5

June

2009)
[PDF]

Mitochondrial function as an emerging 'target of interest' for cancer treatment
EA Sausville
Current Opinion in Investigational Drugs 2009, 10:523-525 (5

June

2009)
[PDF]

Dendritic cells in immunotherapy of established cancer: Roles of signals 1, 2, 3 and 4
P Kalinski
Current Opinion in Investigational Drugs 2009, 10:526-535 (5

June

2009)
[PDF]

The mechanism of action of plitidepsin
MJ Muoz-Alonso, L Gonzlez-Santiago, T Mart-nez, A Losada, CM Galmarini, A Muoz
Current Opinion in Investigational Drugs 2009, 10:536-542 (5

June

2009)
[PDF]

The IL-17/IL-23 axis of inflammation in cancer: Friend or foe?
N Martin-Orozco, C Dong
Current Opinion in Investigational Drugs 2009, 10:543-549 (5

June

2009)
[PDF]

Hyperthermia as an immunotherapy strategy for cancer
JJ Skitzki, EA Repasky, SS Evans
Current Opinion in Investigational Drugs 2009, 10:550-558 (5

June

2009)
[PDF]

The development and testing of aptamers for cancer
AS Barbas, RR White
Current Opinion in Investigational Drugs 2009, 10:572-578 (5

June

2009)
[PDF]

Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies
S Khubchandani, MS Czuczman, FJ Hernandez-Ilizaliturri
Current Opinion in Investigational Drugs 2009, 10:579-587 (5

June

2009)
[PDF]

GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies
T Robak
Current Opinion in Investigational Drugs 2009, 10:588-596 (5

June

2009)
[PDF]

Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer
Y Krupitskaya, HA Wakelee
Current Opinion in Investigational Drugs 2009, 10:597-605 (5